(b) Results from multivariate analyses
| ALZ or CLA | . | . | . | . | . | 3.78 (0.79, 18.00) |
. |
|---|---|---|---|---|---|---|---|
| 1.88 (0.33, 10.73) |
Anti-CD20 agents |
3.25
(1.46, 7.24) |
. | . | 0.91 (0.39, 2.12) |
1.27 (0.31, 5.13) |
. |
| 3.64 (0.65, 20.46) |
1.88 (0.33, 10.73) |
DMF | 0.87 (0.37, 2.05) |
0.71 (0.30, 1.69) |
1.07 (0.40, 2.85) |
. | 1.12 (0.44, 2.89) |
| 3.48 (0.59, 20.33) |
3.64 (0.65, 20.46) |
0.96 (0.48, 1.90) |
FNG | . | 0.68 (0.16, 2.82) |
0.94 (0.25, 3.57) |
. |
| 2.19 (0.38, 12.49) |
3.48 (0.59, 20.33) |
0.60 (0.32, 1.14) |
0.63 (0.27, 1.49) |
NTZ | 1.27 (0.51, 3.19) |
2.25 (0.60, 8.42) |
. |
| 2.59 (0.47, 14.12) |
2.19 (0.38, 12.49) |
0.71 (0.41, 1.23) |
0.75 (0.35, 1.57) |
1.18 (0.62, 2.25) |
No DMT | 1.69 (0.66, 4.38) |
0.65 (0.15, 2.92) |
| 3.78 (0.79, 18.00) |
2.59 (0.47, 14.12) |
1.04 (0.50, 2.18) |
1.09 (0.48, 2.49) |
1.73 (0.80, 3.76) |
1.46 (0.75, 2.84) |
Platform therapy | . |
| 3.18 (0.49, 20.81) |
3.78 (0.79, 18.00) |
0.87 (0.39, 1.97) |
0.91 (0.32, 2.58) |
1.46 (0.54, 3.94) |
1.23 (0.50, 2.99) |
0.84 (0.30, 2.39) |
TRF |
On the upper triangle, the effect size are direct comparisons; the effect sizes presented on lower triangle are network meta-analyses (indirect comparison). Comparisons should be read from left to right (example for upper triangle: OR (95% CI) of developing COVID-19 in anti-CD20 agents compared to DMF is 3.25 (1.46, 7.24); example for lower triangle: OR (95% CI) of developing COVID-19 in the ALZ or CLA group compared to anti-CD20 agents is 1.88 (0.33, 10.73). Platform therapy: interferon and glatiramer acetate; anti-CD20 agents: rituximab and ocrelizumab. ALZ: alemtuzumab; CLA: cladribine; DMF: dimethyl fumarate; FNG: fingolimod; NTZ: natalizumab; TRF: teriflunomide; DMT: disease-modifying therapy.